Powder: -20°C for 3 years
In solvent: -80°C for 2 years
Rogaratinib is an aberrant inhibitor of fibroblast growth factor receptor (FGFR). Rogaratinib is as an orally available, selective and potent inhibitor of FGFR-1, -2 and -3 kinase activity.
Description | Rogaratinib is an aberrant inhibitor of fibroblast growth factor receptor (FGFR). Rogaratinib is as an orally available, selective and potent inhibitor of FGFR-1, -2 and -3 kinase activity. |
In vitro | A novel pan-FGFR inhibitor, rogaratinib, in biochemical, cellular and in vivo efficacy studies in a variety of preclinical cancer models.?In vitro kinase activity assays demonstrate that rogaratinib potently and selectively inhibits the activity of FGFRs 1, 2, 3 and 4.?In line with this, rogaratinib reduced proliferation in FGFR-addicted cancer cell lines of various cancer types including lung, breast, colon and bladder cancer.?FGFR and ERK phosphorylation interruption by rogaratinib treatment in several FGFR-amplified cell lines suggests that the anti-proliferative effects are mediated by FGFR/ERK pathway inhibition[1]. |
Synonyms | BAY1163877 |
Molecular Weight | 466.56 |
Formula | C23H26N6O3S |
CAS No. | 1443530-05-9 |
Powder: -20°C for 3 years
In solvent: -80°C for 2 years
DMSO: 5.5 mg/mL (11.78 mM), Need ultrasonic
( < 1 mg/ml refers to the product slightly soluble or insoluble )
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
Rogaratinib 1443530-05-9 Angiogenesis Tyrosine Kinase/Adaptors FGFR inhibit BAY 1163877 Fibroblast growth factor receptor BAY-1163877 BAY1163877 Inhibitor inhibitor